Report top-line results from the Phase 3 GENESIS trial in stem-cell mobilization
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“top-line data, including full primary and secondary efficacy endpoints, is anticipated in early second quarter of 2021”
What we found
Evidence strength A What the grades mean
Later filings state the GENESIS Phase 3 top-line results were announced in May 2021, before the June 30, 2021 deadline. The exact day is not given.
-
A BioLineRx Ltd. 6-K filed 2021-08-18
“Following the overwhelmingly positive results from our Phase 3 GENESIS trial of Motixafortide in stem-cell mobilization that we” ✓ confirmed on the page
-
A BioLineRx Ltd. 20-F filed 2022-03-16
“In May 2021, we announced positive top-line results from the Phase 3 trial.” ✓ confirmed on the page
-
A BioLineRx Ltd. 20-F filed 2022-03-16
“top-line results announced May 2021 showed highly statistically significant evidence across all primary and secondary” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Top-line GENESIS Phase 3 trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you BioLineRx Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BLRX-024230 · Corrections policy